清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature

伊库利珠单抗 血栓性微血管病 医学 非典型溶血尿毒综合征 抗磷脂综合征 内科学 血液透析 补体系统 免疫学 胃肠病学 血栓形成 抗体 疾病
作者
Nina Kello,Lara El Khoury,Galina S. Marder,Richard Alan Furie,Ekaterini Zapantis,Diane Lewis Horowitz
出处
期刊:Seminars in Arthritis and Rheumatism [Elsevier BV]
卷期号:49 (1): 74-83 被引量:172
标识
DOI:10.1016/j.semarthrit.2018.11.005
摘要

Thrombotic microangiopathy (TMA) is a life-threatening, albeit infrequent, complication of systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS). Recommendations for the treatment of SLE- and APS-related secondary TMA are currently based solely on case reports and expert opinion. Unfortunately, interventions may not yield timely results or effectively halt the progression of TMA. Since complement activation plays a key role in the pathogenesis of secondary TMA due to SLE, APS, a therapy that targets the complement pathway is an attractive intervention. Eculizumab, a recombinant, fully humanized IgG2/IgG4 monoclonal antibody inhibits C5 activation and is FDA-approved for PNH and atypical HUS (aHUS). However, limited case reports are available on its use in treatment of secondary TMA. We present the largest case series to date that includes 9 patients with SLE and/or APS who were successfully treated with eculizumab for refractory secondary TMA. In this case series, we report significant responses in hematology values, renal function and other organs following treatment with eculizumab. At 4 weeks, 75% improvement in platelet counts was observed in 78% of patients. Two-thirds of patients demonstrated >75% improvement of haptoglobin and LDH at four weeks. At 4 weeks, eGFR improved by 25% in half of the patients, and 43% had reductions in proteinuria. Two of 3 patients that required hemodialysis were able to be taken off hemodialysis. Based on these observations, we suggest that eculizumab may be a potential treatment option for acutely ill patients with secondary TMA due to SLE and/or APS who have failed standard of care. A collective approach is needed to better elucidate the role and optimal timing of eculizumab use in the management of TMA complicating SLE and/or APS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
junzzz完成签到 ,获得积分10
10秒前
11秒前
见物思理完成签到 ,获得积分10
16秒前
如懿完成签到,获得积分10
16秒前
如意亦瑶完成签到,获得积分10
18秒前
19秒前
27秒前
拼搏幻柏完成签到,获得积分10
28秒前
YNILY完成签到 ,获得积分10
33秒前
35秒前
岳晓燕完成签到 ,获得积分10
38秒前
44秒前
48秒前
luoqin完成签到 ,获得积分10
51秒前
52秒前
怼怼完成签到 ,获得积分10
52秒前
55秒前
机智的妙芹完成签到,获得积分10
57秒前
1分钟前
1分钟前
1分钟前
1分钟前
zxdzaz完成签到 ,获得积分10
1分钟前
成就小蜜蜂完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
夕阳下仰望完成签到 ,获得积分10
1分钟前
1分钟前
典雅涵瑶发布了新的文献求助10
1分钟前
稳重的秋天完成签到,获得积分10
1分钟前
1分钟前
留胡子的翠容完成签到,获得积分10
1分钟前
1分钟前
典雅涵瑶完成签到,获得积分10
1分钟前
1分钟前
ww完成签到,获得积分10
1分钟前
1分钟前
nanjing01完成签到 ,获得积分10
2分钟前
打打的应助被seeyou14采纳,获得20
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185496
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834498
捐赠科研通 7783092
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558949
邀请新用户注册赠送积分活动 2481346